Discovery of a Novel CRBN-Recruiting cGAS PROTAC Degrader for the Treatment of Ulcerative Colitis
Journal of Medicinal Chemistry · 13.03.2025 · 68 (5) · 5551-5572
DOI: 10.1021/acs.jmedchem.4c02774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 27.02.2025. Verfasst von Peng He und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Membrane Biology, School of Pharmaceutical Sciences, Tsinghua-Peking Center for Life Sciences, Key Laboratory of Bioorganic P…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Nucleotidyltransferases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Noncommunicable Chronic Diseases-National Science and Technology Major Project, Beijing Outstanding Young Scientist Program.
Abstract (Originalsprache)
Cyclic GMP-AMP synthase (cGAS), a critical cytosolic DNA sensor initiating innate immune responses in the presence of cytosolic DNA, is increasingly recognized as a promising therapeutic target for ulcerative colitis (UC). Here, we reported the design, synthesis, structure-activity relationship exploration and biological evaluation of a novel class of CRBN-recruiting cGAS-targeting PROTAC degraders. Among them, TH35 exhibited the most favorable degradation profile, achieving potent and selective degradation of cGAS, and markedly attenuated dsDNA-induced activation of cGAS signaling in both human and murine cells, with minimal cytotoxic effects. In vivo, TH35 demonstrated superior therapeutic efficacy in a dextran sulfate sodium (DSS)-induced mouse model of UC compared to the corresponding cGAS inhibitor, while also displaying acceptable pharmacokinetic properties. Collectively, TH35 as the first CRBN-recruiting cGAS PROTAC holds promise for augmenting anti-inflammatory responses and offers a new avenue for treating cGAS-driven inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Membrane Biology, School of Pharmaceutical Sciences, Tsinghua-Peking Center for Life Sciences, Key Laboratory of Bioorganic Phosphorous Chemistry and Chemical Biology (Ministry of Education), Tsi…
ORCID-Profile: Peng He, Chengming Wen, Hang Yin
Förderung
- National Natural Science Foundation of China
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Beijing Outstanding Young Scientist Program
- the China Postdoctoral Science Foundation
- the Postdoctoral Fellowship Program of CPSF
- the Natural Science Foundation of Beijing, China
Zitieren
APA
He, P., Wen, C., Zhang, X., & Yin, H. (2025). Discovery of a Novel CRBN-Recruiting cGAS PROTAC Degrader for the Treatment of Ulcerative Colitis. Journal of Medicinal Chemistry, 68(5), 5551-5572. https://doi.org/10.1021/acs.jmedchem.4c02774
Vancouver
He P, Wen C, Zhang X, Yin H. Discovery of a Novel CRBN-Recruiting cGAS PROTAC Degrader for the Treatment of Ulcerative Colitis. Journal of Medicinal Chemistry. 2025;68(5):5551-5572. doi:10.1021/acs.jmedchem.4c02774
BibTeX
@article{He2025,
author = {He, Peng and Wen, Chengming and Zhang, Xinyu and Yin, Hang},
title = {Discovery of a Novel CRBN-Recruiting cGAS PROTAC Degrader for the Treatment of Ulcerative Colitis},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {5},
pages = {5551--5572},
doi = {10.1021/acs.jmedchem.4c02774}
}
EUVIMED